E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bacterial Infection in hospitalized children |
|
E.1.1.1 | Medical condition in easily understood language |
Bacterial Infection in children |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10004044 |
E.1.2 | Term | Bacterial infection NOS |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10004043 |
E.1.2 | Term | Bacterial infection in conditions classified elsewhere and of unspecified site |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the pharmacokinetics (PK) of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the safety and tolerability of single dose administration of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive),
- To enable dose estimation for patients less than 3 months of age,
- To enable dose selection for a pediatric phase 3 study. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Hospitalized male and female patients in 3 age cohorts from 3 months to 11 years of age (inclusive) who will be receiving at least 24 hours of appropriate non-investigational intravenous anti-infective treatment other than glycopeptide antibiotics for known or suspected bacterial infections. Patients with urinary tract infections due to Gram-positive organisms may be enrolled.
2. Each patient’s parent(s)/legal guardian(s) must be willing and able to provide a signed and dated written informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. If required by the local IRB, assent of the patients in the two older cohorts will be obtained.
3. Patients and if required by local/site regulations their parent(s)/legal guardian(s) must be willing and able, if discharged from the hospital, to return to the hospital or a designated clinic for scheduled visits, treatment, laboratory tests and other out-patient procedures as required by the protocol.
4. Patients must be expected to survive with appropriate antibiotic therapy and appropriate supportive care throughout the study.
5. Patients must have an audiologic assessment within 7 days prior to the study drug infusion consisting of symmetric hearing testing utilizing evoked otoacoustic emissions and acoustic immittance measures. |
|
E.4 | Principal exclusion criteria |
1.Treatment with an investigational drug within 30 days preceding the first dose of study medication.
2.Patients who are currently receiving intravenous vancomycin or other glycopeptide antibiotics. Dalbavancin may be administered 8 hours after the last dose of vancomycin. Vancomycin or other glycopeptide antibiotics should not be given during the 7 day period following administration of dalbavancin. If intravenous vancomycin or other glycopeptide use is unavoidable during the 7 day period following administration of dalbavancin, this should be documented as a concomitant medication.
3.Patients with any clinically significant abnormality following review of screening laboratory data other than that associated with their underlying disease. Such abnormalities include aminotransferases (AST, ALT) >5 x ULN; total bilirubin and/or alkaline phosphatase >2 x ULN.
4.Albumin < half lower limit of normal.
5.Patients who are less than one year of age and were born with gestational age of less than 32 weeks.
6.Patients diagnosed with cystic fibrosis.
7.Positive urine (or serum) pregnancy test at screening (post menarchal females only) or after admission (prior to dosing).
8.Patients known to have hypersensitivity to glycopeptides.
9.Patients with calculated creatinine clearance <30 ml/min. Creatinine clearance will be calculated using the Schwartz method:
Children < 1 year: CLCr = (ml/min/1.73m2)= [length (cm) x 0.45]/Scr
Children ≥ 1 year: CLCr = (ml/min/1.73m2)= [length (cm) x 0.55]/Scr
10.Pregnant or nursing females; sexually active females of childbearing potential who are unwilling or unable to use an acceptable method of nonhormonal contraception as outlined in this protocol from at least 14 days prior or hormonal contraception for at least 3 months prior to the dose of study medication until the end of the study and completion of follow-up procedures (female patients to have pregnancy testing are those who are at least 10 years old with menarche and/ or thelarche (beginning of breast development)).
11.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1: 0.5 hours (within thirty minutes after the end of the infusion).
◦ Post -start-of-infusion: 4 hours (± 2 hours) and 12 hours (± 2 hours)
Day 2: 24 hours (Day 2 ± 4 hours) post-start-of-infusion on Day 1.
Day 7: 144 hours (Day 7 ± 2 days) post -start-of-infusion on Day 1.
Day 28: 648 hours (Day 28 4 days) post-start-of-infusion on Day 1. |
|
E.5.2 | Secondary end point(s) |
Safety and tolerability of single dose administration |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
First administration in children in these age groups |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
3 cohorts: Enrollment in Cohort 3 initiated after completion of a safety assessment in Cohorts 1&2 |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |